review · Clinical and Molecular Hepatology

Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)

Chuan Liu
Shenghong Ju
Gao‐Jun Teng
Amr Shaaban Hanafy
Hirayuki Enomoto
Chenghai Liu
Hyung Joon Yim
Yoichi Hiasa
Ivica Grgurević
Zhujun Cao
Antonio Colecchia
Masashi Hirooka
Bingtian Dong
Hiroko Iijima
Xiaoling Lan
Qing‐Lei Zeng
Hong You
Takashi Nishimura
Yu Jun Wong
Changxiang Lai
Chuxiao Shao
Qing Xie
Zhensheng Liu
Yanan Guo
Yuqing Wang
Ying Guo
Jiaojian Lv
Fang Wang
Shirong Liu
Tae Hyung Kim
Jie Li
Liting Zhang
Chuanjun Xu
Yohei Koizumi
Qian Yu
Erhei Dai
Liu Ravaioli
Wei Gou
Bingqiong Wang
Jing Lv
Xiemin Dong
Xiaolong Qi

20248 citationsOpen accessZagazig University

In plain language

The abstract on record is too brief for a reliable plain-language summary, so none has been generated.

Abstract

Treatment with carvedilol significantly reduces the risk of hepatic decompensation in patients with high-risk CSPH stratified by the new model.

Research topics

Liver Disease and Transplantation
Liver Disease Diagnosis and Treatment
Drug-Induced Hepatotoxicity and Protection

Sustainable Development Goals

2Zero Hunger

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

View on publisher site Record on OpenAlex

DOI: 10.3350/cmh.2024.0198

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.

New to MARATTO™? Create a free account.